Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser’s post-transplant portfolio of NGS products.
In addition to North America and Europe, Thermo Fisher will now exclusively market and sell Devyser’s transplantation products under combined brands also in Brazil.
“We are very excited to enter into this agreement. Up to now, our products have not been available in the large Brazilian market, and we are highly optimistic about future sales in the country, which has the second-highest number of transplanted organs globally. The agreement provides laboratories in Brazil access to genetic tests that are simple, fast, and easy to use. We are convinced that Thermo Fisher, the leading innovator in the HLA industry, will do this very successfully,” says Fredrik Alpsten, CEO at Devyser.
In Brazil, a total of approximately 6,000 kidneys are transplanted every year.”
In Brazil, a total of approximately 6,000 kidneys are transplanted every year. Only the US has a higher number of transplantations. The agreement includes One Lambda Devyser Chimerism for early detection of graft rejection in stem cell transplanted patients and One Lambda Devyser Accept cfDNA, a novel test for detecting donor-derived cell-free DNA in blood samples from kidney transplant patients.
Photo of Fredrik Alpsten: Devyser
